University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.
JAMA Netw Open. 2024 Feb 5;7(2):e240243. doi: 10.1001/jamanetworkopen.2024.0243.
Continuous kidney replacement therapy (CKRT) is increasingly used in youths with critical illness, but little is known about longer-term outcomes, such as persistent kidney dysfunction, continued need for dialysis, or death.
To characterize the incidence and risk factors, including liberation patterns, associated with major adverse kidney events 90 days after CKRT initiation (MAKE-90) in children, adolescents, and young adults.
DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter cohort study was conducted among patients aged 0 to 25 years from The Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) registry treated with CKRT for acute kidney injury or fluid overload from 2015 to 2021. Exclusion criteria were dialysis dependence, concurrent extracorporeal membrane oxygenation use, or receipt of CKRT for a different indication. Data were analyzed from May 2 to December 14, 2023.
Patient clinical characteristics and CKRT parameters were assessed. CKRT liberation was classified as successful, reinstituted, or not attempted. Successful liberation was defined as the first attempt at CKRT liberation resulting in 72 hours or more without return to dialysis within 28 days of CKRT initiation.
MAKE-90, including death or persistent kidney dysfunction (dialysis dependence or ≥25% decline in estimated glomerular filtration rate from baseline), were assessed.
Among 969 patients treated with CKRT (529 males [54.6%]; median [IQR] age, 8.8 [1.7-15.0] years), 630 patients (65.0%) developed MAKE-90. On multivariable analysis, cardiac comorbidity (adjusted odds ratio [aOR], 1.60; 95% CI, 1.08-2.37), longer duration of intensive care unit admission before CKRT initiation (aOR for 6 days vs 1 day, 1.07; 95% CI, 1.02-1.13), and liberation pattern were associated with MAKE-90. In this analysis, patients who successfully liberated from CKRT within 28 days had lower odds of MAKE-90 compared with patients in whom liberation was attempted and failed (aOR, 0.32; 95% CI, 0.22-0.48) and patients without a liberation attempt (aOR, 0.02; 95% CI, 0.01-0.04).
In this study, MAKE-90 occurred in almost two-thirds of the population and patient-level risk factors associated with MAKE-90 included cardiac comorbidity, time to CKRT initiation, and liberation patterns. These findings highlight the high incidence of adverse outcomes in this population and suggest that future prospective studies are needed to better understand liberation patterns and practices.
连续肾脏替代疗法(CKRT)在患有危重病的青少年中越来越多地使用,但对 90 天后的长期结果(如持续性肾功能障碍、持续需要透析或死亡)知之甚少。
描述主要不良肾脏事件 90 天后(MAKE-90)与 CKRT 开始相关的发生率和风险因素,包括释放模式,在儿童、青少年和年轻人中。
设计、地点和参与者:这是一项国际、多中心队列研究,纳入了来自全球肾脏替代治疗探索协作组织(WE-ROCK)登记处的年龄在 0 至 25 岁之间的患者,这些患者在 2015 年至 2021 年间因急性肾损伤或液体超负荷接受 CKRT 治疗。排除标准为依赖透析、同时使用体外膜氧合或接受 CKRT 治疗不同的指征。数据于 2023 年 5 月 2 日至 12 月 14 日进行分析。
评估患者的临床特征和 CKRT 参数。CKRT 释放分为成功、重新开始或未尝试。成功释放是指 CKRT 释放的第一次尝试导致在 CKRT 开始后 28 天内没有返回透析的 72 小时或更长时间。
评估了 MAKE-90,包括死亡或持续性肾功能障碍(透析依赖或估计肾小球滤过率基线下降≥25%)。
在接受 CKRT 治疗的 969 例患者中(529 例男性[54.6%];中位[IQR]年龄,8.8[1.7-15.0]岁),有 630 例(65.0%)发生了 MAKE-90。多变量分析显示,合并心脏疾病(调整后的优势比[OR],1.60;95%CI,1.08-2.37)、CKRT 开始前 ICU 住院时间较长(与 1 天相比,6 天的 OR,1.07;95%CI,1.02-1.13)和释放模式与 MAKE-90 相关。在这项分析中,与尝试和失败的释放(OR,0.32;95%CI,0.22-0.48)以及没有释放尝试的患者(OR,0.02;95%CI,0.01-0.04)相比,在 28 天内成功从 CKRT 中释放的患者发生 MAKE-90 的几率较低。
在这项研究中,近三分之二的患者发生了 MAKE-90,与 MAKE-90 相关的患者水平风险因素包括心脏合并症、CKRT 开始时间和释放模式。这些发现强调了该人群中不良结局的高发生率,并表明需要未来的前瞻性研究来更好地了解释放模式和实践。